Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Payables (2016 - 2026)

Summit Therapeutics filings provide 13 years of Payables readings, the most recent being $27.5 million for Q1 2026.

  • Quarterly Payables rose 451.64% to $27.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27.5 million through Mar 2026, up 451.64% year-over-year, with the annual reading at $20.3 million for FY2025, 337.7% up from the prior year.
  • Payables hit $27.5 million in Q1 2026 for Summit Therapeutics, up from $20.3 million in the prior quarter.
  • Across five years, Payables topped out at $103.3 million in Q2 2024 and bottomed at $710000.0 in Q1 2023.
  • Average Payables over 5 years is $22.3 million, with a median of $7.0 million recorded in 2022.
  • The largest annual shift saw Payables plummeted 89.8% in 2023 before it soared 10370.11% in 2024.
  • Summit Therapeutics' Payables stood at $20.1 million in 2022, then tumbled by 86.75% to $2.7 million in 2023, then soared by 73.83% to $4.6 million in 2024, then surged by 337.7% to $20.3 million in 2025, then surged by 35.76% to $27.5 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Payables are $27.5 million (Q1 2026), $20.3 million (Q4 2025), and $22.2 million (Q3 2025).